POLD1 and cancer: Our findings indicate that constitutional heterozygous pathogenic variants in the exonuclease domain of POLD1 have a mild effect on somatic and germline mutation rates in humans, although heterozygous carriers of POLD1 exonuclease domain pathogenic variants are predisposed to develop hyper- or ultra-mutated cancers.